The short answer
Calcium can be used during abaloparatide treatment when dietary intake is inadequate. The amount should fit your treatment plan because abaloparatide can raise blood and urine calcium. The evidence supports appropriate supplementation and monitoring, not unlimited doses or a blanket instruction to avoid the supplement.
What this answer covers
Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
- Supplement or preparation
- calcium
- Medication ingredient
- abaloparatide
Why are they used together?
The TYMLOS label recommends calcium and vitamin D if dietary intake is insufficient. This supports checking whether you need calcium and how much you already receive; it does not mean everyone needs the same additional dose.
What did studies show?
Participants in the pivotal osteoporosis trial received calcium and vitamin D. High calcium occurred during treatment, and the protocol allowed clinicians to change supplements or treatment when needed. Because supplement doses were not randomized, the trial cannot quantify the extra risk caused by either supplement alone.
What needs monitoring?
The prescribing information warns about existing high blood calcium and conditions that raise calcium. Kidney function, urinary calcium and a history of stones can matter. The FDA review documents that supplements were reduced or stopped in some participants after hypercalcemia developed; these were clinician-directed decisions.
Does timing solve the concern?
No tested separation interval for preventing high calcium was established by these sources. The injection does not share the intestinal-binding interaction seen with some oral medicines. Follow your prescriber’s supplement plan and discuss abnormal results instead of changing the injection or supplements on your own.
Evidence and practical considerations
Timing & monitoring
Use calcium supplementation when intake is inadequate, with dose and monitoring tailored to the abaloparatide treatment plan.
- Exact scope
- Calcium as an oral product, retaining the exact formulation and dose limitations in the article. with Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
- Medication form and route
- subcutaneous abaloparatide injection
- Timing or duration
- During osteoporosis treatment; no evidence-based dose-separation interval established.
What remains uncertain
- The studies gave calcium and vitamin D as background care rather than randomizing supplement doses. They establish a need for monitored co-use but not a pair-specific high-dose threshold or an isolated excess-risk estimate.
Factors that may matter: pre-existing hypercalcemia; renal impairment; hypercalciuria or kidney-stone history.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women and men with osteoporosis at high fracture risk.
Recommends calcium and vitamin D if intake is inadequate; warns about hypercalcemia, hypercalciuria and post-injection orthostatic hypotension.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
No specific drug-drug interaction studies were performed. The label does not isolate the extra risk from a particular supplement dose.
Source 2: primary clinical research
jamanetwork.com · Source check Sep 10, 2026
Population: 2,463 postmenopausal women with osteoporosis.
Hypercalcemia occurred during supported osteoporosis treatment; the protocol allowed supplement or treatment changes for high calcium.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
Supplement doses were not randomized, so the study cannot calculate the independent risk added by calcium or vitamin D.
Source 3: regulatory clinical review
accessdata.fda.gov · Source check Sep 10, 2026
Population: Participants in pivotal osteoporosis trials reviewed for initial approval.
Calcium and vitamin D supplements were reduced or stopped for hypercalcemia in 1.7% of abaloparatide-treated participants.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
Regulatory analysis of the same trial program, not an independent replication; no randomized supplement dose comparison.
Research assessment: · Open full citations ↗
Side effects & toxicity
Abaloparatide can raise blood and urinary calcium. Supplement amounts may need adjustment if calcium becomes elevated; an independent excess risk from a specific supplement dose is not established.
- Exact scope
- Calcium as an oral product, retaining the exact formulation and dose limitations in the article. with Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
- Medication form and route
- subcutaneous abaloparatide injection
- Timing or duration
- Monitoring during treatment; laboratory sampling in the trials distinguished pre-dose and post-dose measurements.
What remains uncertain
- The studies gave calcium and vitamin D as background care rather than randomizing supplement doses. They establish a need for monitored co-use but not a pair-specific high-dose threshold or an isolated excess-risk estimate.
Factors that may matter: pre-existing hypercalcemia; renal impairment; supplement dose.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women and men with osteoporosis at high fracture risk.
Recommends calcium and vitamin D if intake is inadequate; warns about hypercalcemia, hypercalciuria and post-injection orthostatic hypotension.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
No specific drug-drug interaction studies were performed. The label does not isolate the extra risk from a particular supplement dose.
Source 2: primary clinical research
jamanetwork.com · Source check Sep 10, 2026
Population: 2,463 postmenopausal women with osteoporosis.
Hypercalcemia occurred during supported osteoporosis treatment; the protocol allowed supplement or treatment changes for high calcium.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
Supplement doses were not randomized, so the study cannot calculate the independent risk added by calcium or vitamin D.
Source 3: regulatory clinical review
accessdata.fda.gov · Source check Sep 10, 2026
Population: Participants in pivotal osteoporosis trials reviewed for initial approval.
Calcium and vitamin D supplements were reduced or stopped for hypercalcemia in 1.7% of abaloparatide-treated participants.
How this applies: Direct osteoporosis co-use context for calcium; supplement-specific dose causality is not isolated.
Regulatory analysis of the same trial program, not an independent replication; no randomized supplement dose comparison.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original sources checked; exact preparation and timing limits assessed; consumer article drafted and existing checker statements reconciled. | |
| Research summary published |
Article revision: e7b27ab7b3a03f70
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.